Oncopole Claudius Regaud — Clinical Trial Site

472 Registered trials

208 Currently recruiting

Organisation

Oncopole Claudius Regaud

Location

Toulouse Cedex 9, France

Identifier

ORG-100010774

Address

1 Avenue Irene Joliot Curie, 31100, France

Departments

-
#2003 Hématologie
#2021: Department of Hematology
#2105:Hématologie
#4001: Neurologie
#4004: Service d’hématologie
03303: Service d´Oncologie Médicale
1001: Hematology
1006: Nephrologie et transplantation d’organes
1203 Nuclear Medicine
1204: Oncologie Médicale
1403: Nuclear medicine and metabolic irradiation
2057: Medecine Interne
2406:Hématologie
31
3106: Service d´Oncologie Médicale
33009: Oncologie Médicale
4004:Oncologie Médicale
4105:Service d’Hématologie
Breast Oncology
Bureau des Essais Cliniques
Cancer Comprehensive Center Medical Oncology
Cancérologie
Chirurgie
Clinical Research Unit
Département d' Hématologie
Département d'hématologie
Département d'Oncologie Médicale
Departement d’ Oncologie Medicale
Département d’Hématologie
Département d’hématologie / Unité de médecine interne
Département d’oncologie médicale
Département de dermatologie
Département de radiothérapie
Département médical d'oncologie
Departement oncologie medicale
Département Oncologie Médicale - Unité de phase précoce
Department Medical Oncology
Department of Hematology
Department of Oncology
Dépatement hématologie
dermatologie
DERMATOLOGIE IUCT
Early Phase Unit
FR10018: Hematologie
Gynaecologic Oncology
Gynecological surgery
GYNECOLOGIE
Hématologie
Hematology
Hematology Department
Institut Universitaire du Cancer
Institut Universitaire du Cancer de Toulouse-Oncopole Unité de recherche clinique
Institut Universitaire du Cancer I.U.C.Toulouse – Oncopôle Département Hématologie
Internal Medecine
Internal Medicine
Internal Medicine Unit
IUCT - Rangueil - Larrey Oncologie Médicale Digestive
IUCT Oncopole
IUCT-O
Médecine Générale
Médecine interne
medecine nucléaire
Médecine Nucléaire/Oncologie Médicale Digestive
medecine nuclear department
Medical Digestive Oncology
Medical Imaging
Medical Oncology
Medical oncology - Early Phase Unit
Medical Oncology Department
N/A
NA
Neuro - Oncology
Not applicable
Nuclear Medicine
Nuclear Medicine and Metabolic Irradiation/ Digestive Oncology
Nuclear medicine unit
Onclologie médicale
Oncologie
Oncologie médical
Oncologie Médicale
Oncologie médicale - Unité de phases précoces
ONCOLOGIE OPTION MEDICALE
Oncologie Radiothérapie
Oncologue
Oncology
Oncology Department
Oncology-radiotherapy
Oncopole Claudius Regaud IUCT-O
Pulmonology
Radiation Oncology
Radiotherapie
radiotherapy
Radiotherapy department
Service d Hematologie
Service d'Hématologie
Service d'oncologie
Service d'oncologie médicale
Service d’hématologie
Service d’Oncologie
Service d’Oncologie Médicale
Service de Médecine Interne
Service de Pneumologie et Allergologie
Service Dermatologie
Service Hématologie
Service hématologie-médecine interne
Service Oncologie
Supportive care
Surgery
Unité de recherche clinique
Unité de recherche clinique (IUCT-0)
Unité de recherche clinique, Oncopole Claudius Regaud
Urology
Z97FR10004: Hématologie

Clinical trials at this site (472)

Search interface

A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa… Recruiting

2024-517979-20-00 Advanced Breast Cancer Metastatic Breast Cancer 9 2026-03-04
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting

2025-523297-16-00 Non-Hodgkin Lymphoid Malignancies (NHLs) 1 2026-02-27
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin… Recruiting

2025-521606-18-00 Ovarian Cancer 4 2026-01-29
Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting

2024-515023-11-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2026-01-22
A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting

2025-521441-24-00 Advanced or Metastatic Solid Tumors 7 2026-01-19
Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting

2024-519404-27-00 IDH-mutant grade 2 or 3 astrocytoma 5 2026-01-16
Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting

2022-501562-22-01 Triple-negative breast cancer (TNBC) patients at high r 4 2026-01-05
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting

2024-512503-39-00 Arm A (AML): Newly diagnosed de novo Acute myeloid leuk 6 2025-12-19
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Momelotinib in VEXAS syndrome Recruiting

2024-519779-24-00 VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, 4 2025-11-25
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t… Recruiting

2023-510568-11-00 High grade brain tumors 9 2025-11-18
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-11-14
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting

2025-522169-31-00 Adult Patients with HER2-IHC3+ selected solid cancers ( 4 2025-10-30
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim… Recruiting

2024-517140-65-00 Multiple Myeloma (MM). 9 2025-10-23
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c… Recruiting

2025-522656-68-00 Metastatic breast cancers 6 2025-10-15
Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS… Recruiting

2025-521147-21-00 Lung Cancer 4 2025-10-08
A Phase 1/1b Study of IAM1363 in HER2 Cancers Recruiting

2024-519188-17-00 Relapsed/refractory malignancy with documented diagnosi 1 2025-10-07
A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients… Recruiting

2024-514152-32-00 Relapsed or Refractory Chronic Lymphocytic Leukemia (R/ 3 2025-10-06
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02